Discontinuation report APO-LAMIVUDINE HBV
Report ID | 60563 |
Drug Identification Number | 02393239 |
Brand name | APO-LAMIVUDINE HBV |
Common or Proper name | LAMIVUDINE |
Company Name | APOTEX INC |
Market Status | MARKETED |
Active Ingredient(s) | LAMIVUDINE |
Strength(s) | 100MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 60 BTL |
ATC code | J05AF |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2019-07-04 |
Actual discontinuation date | 2019-12-20 |
Remaining supply date | 2019-12-20 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.